Asia
Zhejiang Garden Biopharma Gets Registration Certificate for Ezetimibe and Atorvastatin Calcium Tablets
Zhejiang Garden Biopharmaceutical (SHE:300401) received a drug registration certificate from China's National Medical Products Administration for its ezetimibe and atorvastatin calcium tablets, according to a Shenzhen bourse filing on Tuesday.The drug is used as a treatment for hypercholesterolemia and homozygous familial hypercholesterolemia.The approval is valid until May 11, 2031.
SHE:300401
